Reply

Drs Azad and Takkar have made 3 points regarding the manuscript reporting the 12-month outcomes of the VIBRANT Study. The first is that they feel the study should have used an as-needed dosing regimen rather than bimonthly fixed dosing regimen between months 6 and 12 because this would have provided better information as to how many injections of aflibercept are needed to compare with the number of ranibizumab injections required between 6 and 12 months in the BRAVO study.1,2 There are pros and cons to every treatment regimen.

Source: Ophthalmology - September 21, 2016 Category: Opthalmology Authors: W. Lloyd Clark, David S. Boyer, Jeffrey S. Heier, David M. Brown, Julia A. Haller, Robert Vitti, Husain Kazmi, Alyson J. Berliner, Kristine Erickson, Karen W. Chu, Yuhwen Soo, Yenchieh Cheng, Peter A. Campochiaro Tags: Correspondence Source Type: research